These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 29188612)

  • 21. Cytochrome CYP2C19 polymorphism and risk of adverse clinical events in clopidogrel-treated patients: a meta-analysis based on 23,035 subjects.
    Mao L; Jian C; Changzhi L; Dan H; Suihua H; Wenyi T; Wei W
    Arch Cardiovasc Dis; 2013 Oct; 106(10):517-27. PubMed ID: 24080325
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Relevance of CYP2C19 2 regarding platelet reactivity in patients with acute coronary syndrome treated with clopidogrel].
    Cano P; Consuegra-Sánchez L; Conesa P; Torres-Moreno D; Jaulent L; Dau D; Picó F; Villegas M
    Med Clin (Barc); 2014 Jul; 143(1):6-12. PubMed ID: 23850044
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial.
    Wallentin L; James S; Storey RF; Armstrong M; Barratt BJ; Horrow J; Husted S; Katus H; Steg PG; Shah SH; Becker RC;
    Lancet; 2010 Oct; 376(9749):1320-8. PubMed ID: 20801498
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CYP2C19 polymorphisms and coronary heart disease risk factors synergistically impact clopidogrel response variety after percutaneous coronary intervention.
    Liu T; Yin T; Li Y; Song LQ; Yu J; Si R; Zhang YM; He Y; Guo WY; Wang HC
    Coron Artery Dis; 2014 Aug; 25(5):412-20. PubMed ID: 24608794
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Analysis of the effect of CYP2C19 gene properties on the anti-platelet aggregation of clopidogrel after carotid artery stenting under network pharmacology.
    Li P; Cao M; Liu L; Chen L; Liang S; Wang Y
    BMC Pharmacol Toxicol; 2024 Jun; 25(1):34. PubMed ID: 38845014
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Potential Usefulness of Clopidogrel Pharmacogenetics in Cerebral Endovascular Procedures and Carotid Artery Stenting.
    Duconge J; Hernandez-Suarez DF
    Curr Clin Pharmacol; 2017; 12(1):11-17. PubMed ID: 28245774
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Variant recurrent risk among stroke patients with different CYP2C19 phenotypes and treated with clopidogrel.
    Sun W; Li Y; Li J; Zhang Z; Zhu W; Liu W; Cai Q; Wang X; Cao L; Bai W; Fan X; Ma M; Guo R; Liu X; Xu G
    Platelets; 2015; 26(6):558-62. PubMed ID: 25207801
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CYP2C19 polymorphisms in acute coronary syndrome patients undergoing clopidogrel therapy in Zhengzhou population.
    Guo YM; Zhao ZC; Zhang L; Li HZ; Li Z; Sun HL
    Genet Mol Res; 2016 May; 15(2):. PubMed ID: 27323099
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association between platelet function and recurrent ischemic vascular events after TIA and minor stroke
.
    Zhang J; Zhang J; Sun H; Ming T; Liu X; Cong Y; Li F; Li Z
    Int J Clin Pharmacol Ther; 2017 Oct; 55(10):789-797. PubMed ID: 28766499
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of CYP2C19 polymorphism on clinical outcome following coronary stenting is more important in non-diabetic than diabetic patients.
    Mizobe M; Hokimoto S; Akasaka T; Arima Y; Kaikita K; Morita K; Miyazaki H; Oniki K; Nakagawa K; Ogawa H
    Thromb Res; 2014 Jul; 134(1):72-7. PubMed ID: 24821368
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aspirin plus clopidogrel may reduce the risk of early neurologic deterioration in ischemic stroke patients carrying CYP2C19*2 reduced-function alleles.
    Yi X; Zhou Q; Wang C; Lin J; Chai Z
    J Neurol; 2018 Oct; 265(10):2396-2403. PubMed ID: 30128710
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of Dual-Dose Clopidogrel, Clopidogrel Combined with Tongxinluo Capsule, and Ticagrelor on Patients with Coronary Heart Disease and CYP2C19*2 Gene Mutation After Percutaneous Coronary Interventions (PCI).
    Chen S; Zhang Y; Wang L; Geng Y; Gu J; Hao Q; Wang H; Qi P
    Med Sci Monit; 2017 Aug; 23():3824-3830. PubMed ID: 28783717
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of CYP2C19 genotype testing in clinical use of clopidogrel: is it really useful?
    Zeb I; Krim N; Bella J
    Expert Rev Cardiovasc Ther; 2018 May; 16(5):369-377. PubMed ID: 29589775
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genetic and platelet function testing of antiplatelet therapy for percutaneous coronary intervention: the ARCTIC-GENE study.
    Collet JP; Hulot JS; Cuisset T; Rangé G; Cayla G; Van Belle E; Elhadad S; Rousseau H; Sabouret P; O'Connor SA; Abtan J; Kerneis M; Saint-Etienne C; Barthélémy O; Beygui F; Silvain J; Vicaut E; Montalescot G;
    Eur J Clin Pharmacol; 2015 Nov; 71(11):1315-24. PubMed ID: 26265231
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Besides CYP2C19*2, the variant allele CYP2C9*3 is associated with higher on-clopidogrel platelet reactivity in patients on dual antiplatelet therapy undergoing elective coronary stent implantation.
    Harmsze A; van Werkum JW; Bouman HJ; Ruven HJ; Breet NJ; Ten Berg JM; Hackeng CM; Tjoeng MM; Klungel OH; de Boer A; Deneer VH
    Pharmacogenet Genomics; 2010 Jan; 20(1):18-25. PubMed ID: 19934793
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association of CYP2C19 Polymorphisms with the Clinical Efficacy of Clopidogrel Therapy in Patients Undergoing Carotid Artery Stenting in Asia.
    Zhu WY; Zhao T; Xiong XY; Li J; Wang L; Zhou Y; Gong ZL; Cheng SY; Liu Y; Shuai J; Yang QW
    Sci Rep; 2016 May; 6():25478. PubMed ID: 27137706
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CYP2C19 LOF and GOF-Guided Antiplatelet Therapy in Patients with Acute Coronary Syndrome: A Cost-Effectiveness Analysis.
    Jiang M; You JH
    Cardiovasc Drugs Ther; 2017 Feb; 31(1):39-49. PubMed ID: 27924429
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention.
    Sibbing D; Stegherr J; Latz W; Koch W; Mehilli J; Dörrler K; Morath T; Schömig A; Kastrati A; von Beckerath N
    Eur Heart J; 2009 Apr; 30(8):916-22. PubMed ID: 19193675
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CYP2C19 polymorphisms and clopidogrel efficacy in the secondary prevention of ischemic stroke: a retrospective observational study.
    Lin J; Mo Y; Cai D; Mao D; Fu H; Wei D
    Ann Palliat Med; 2021 Dec; 10(12):12171-12180. PubMed ID: 35016407
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Carriage of cytochrome 2C19 polymorphism is associated with risk of high post-treatment platelet reactivity on high maintenance-dose clopidogrel of 150 mg/day: results of the ACCEL-DOUBLE (Accelerated Platelet Inhibition by a Double Dose of Clopidogrel According to Gene Polymorphism) study.
    Jeong YH; Kim IS; Park Y; Kang MK; Koh JS; Hwang SJ; Kwak CH; Hwang JY
    JACC Cardiovasc Interv; 2010 Jul; 3(7):731-41. PubMed ID: 20650435
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.